loading page

Evaluation of Kidney Function Tests in HIV-Positive Patients Receiving Combined Antiretroviral Therapy
  • +2
  • emre aydın,
  • Fatma Yılmaz Aydın,
  • Yakup Demir,
  • Yaşar Yıldırım,
  • Mustafa Kemal Çelen
emre aydın
Dicle University Medical Faculty
Author Profile
Fatma Yılmaz Aydın
Dicle University Medical Faculty
Author Profile
Yakup Demir
Dicle University Medical Faculty
Author Profile
Yaşar Yıldırım
Dicle University Medical Faculty
Author Profile
Mustafa Kemal Çelen
Dicle University Medical Faculty
Author Profile

Abstract

Introduction: Human Immunodeficiency virus is a chronic infection that attacks the immune system of the human body, particularly CD4 T lymphocytes. Combined antiretroviral therapies are highly effective in virological suppression of human immunodeficiency virus infection. It has been shown that some retroviral therapies have a higher nephrotoxicity potential. As a result of renal injury, serum creatinine increases, and the estimated glomerular filtration rate is reduced. The aim of our study was to assess changes in kidney function during a 24-month period in HIV-positive patients who were begun on combined antiretroviral therapy. Material-method: A total of 127 HIV positive patients were enrolled. The patients were divided into five groups; patients who received no therapy were designated as Group 1; those that received Dolutegravir/Abacavir/Lamivudine combination as Group 2; those that received Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate combination as Group 3; those that received Emtricitabine/Tenofovir Disoproxil Fumarate/Dolutegravir combination as Group 4; and those that received Emtricitabine/Tenofovir Disoproxil Fumarate/Raltegravir combination as Group 5. We compared the effects of these drugs on estimated glomerular filtration rate during a 24-month follow-up period. Results: At the 24th month of therapy, a significant difference was observed between the eGFR levels of the study groups (p:<0.001). eGFR level was significantly higher in Group 4 compared to Groups 1, 2, and 3 (p:0.009, p:<0.001, p:<0.001, respectively) while it was significantly lower in Group 5 than groups 1, 2, and 3 (p:0.005, p:<0.001, p:<0.001, respectively). No significant eGFR difference was found between Group 4 and Group 5 (p>0.05). Serum creatinine level was significantly higher in Groups 4 and 5 compared to the other groups (p<0.001). Conclusion: The use of TDF-containing regimens causes renal dysfunction. Therefore, we recommend close monitoring of renal function, especially in patients treated with TDF.

Peer review status:ACCEPTED

02 Apr 2021Submitted to International Journal of Clinical Practice
03 Apr 2021Submission Checks Completed
03 Apr 2021Assigned to Editor
10 Apr 2021Reviewer(s) Assigned
25 Apr 2021Review(s) Completed, Editorial Evaluation Pending
07 May 20211st Revision Received
10 May 2021Assigned to Editor
10 May 2021Submission Checks Completed
10 May 2021Review(s) Completed, Editorial Evaluation Pending
24 May 2021Reviewer(s) Assigned
10 Jun 2021Editorial Decision: Revise Minor
11 Jun 20212nd Revision Received
12 Jun 2021Submission Checks Completed
12 Jun 2021Assigned to Editor
12 Jun 2021Review(s) Completed, Editorial Evaluation Pending
15 Jun 2021Editorial Decision: Accept